Status:
COMPLETED
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Lead Sponsor:
University of Florida
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
This study will evaluate the role of Gemcitabine and Abraxane in the treatment of resectable and borderline-resectable pancreatic cancer by giving the chemotherapy before surgery.
Detailed Description
This current study proposes to conduct a prospective non-randomized open-label phase II trial using Gemcitabine and Abraxane in the neoadjuvant treatment of resectable and borderline-resectable pancre...
Eligibility Criteria
Inclusion
- • Histologically or cytologically confirmed adenocarcinoma of the pancreas.
- Patients must have locally advanced pancreatic cancer, classified as either low-risk resectable (LR), high-risk resectable (HR) or borderline resectable (BR)
- Age between 18 and 90 years at the time of consent.
- Patients with biliary obstruction must have adequate drainage prior to starting treatment.
- Patients must have ≤ Grade I peripheral neuropathy (CTCAE v 4.0)
- Patients must have ≤ ECOG Performance status 2
- Pretreatment laboratory parameters:
- Absolute granulocyte/neutrophil count (AGC/ANC) ≥ 1.8 thou/mm3
- Platelet count ≥ 100,000/mm3
- Bilirubin \< 2 mg/dl
- ALT/SGPT \< 10x upper limit of normal
- Creatinine \< 3 mg/dl
- Calculated creatinine clearance (via Cockcroft-Gault) \> 30 mL/min
- Baseline CA 19-9 levels
- Signed study specific, IRB stamped informed consent
Exclusion
- • Evidence of any distant metastasis including peritoneal seeding and/or malignant ascites
- Previous irradiation to the abdomen that would compromise the ability to deliver the prescribed treatment
- Prior treatment for pancreatic cancer
- Active, untreated infection
- Surgical resection of the tumor (not including biopsies)
- Other malignancy (except non-melanoma skin cancer) that has not been disease-free for at least 5 years.
- Pregnant and/or breast-feeding women, or patients (men and women) of child-producing potential not willing to use medically acceptable contraception while on treatment and for at least 3 months thereafter.
- Use of anti-epileptics (drugs such as phenytoin, phenobarbitol and carbamazepine)
- ECG abnormality with the following: QTC \>500, left bundle branch block or any other clinically significant finding that would interfere with protocol therapy.
- History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01470417
Start Date
October 1 2011
End Date
October 1 2019
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida Shands Cancer Center
Gainesville, Florida, United States, 32610